MAIA Biotechnology, Inc. 8-K

What Happened

• MAIA Biotechnology, Inc. announced in an 8-K filed May 14, 2026 that it has suspended sales of its common stock under its At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC and provided notice terminating that sales agreement. The sales agreement dates to February 14, 2024; the termination becomes effective seven business days after May 14, 2026 (on or about May 25, 2026).

Key Details

• ATM agent: H.C. Wainwright & Co., LLC.
• Prospectus supplement filed March 28, 2025 authorized up to $11,200,000 of sales under the ATM.
• Since that prospectus supplement, MAIA offered and sold 3,116,012 shares of common stock for gross proceeds of approximately $5,680,924 under the ATM.
• Sales were suspended as of May 14, 2026; termination notice was provided the same day.

Why It Matters

• The ATM was a ready source of capital; terminating it removes that immediate mechanism to raise up to the previously authorized $11.2M.
• Investors should note the company has already issued ~3.12M shares under the program for ~$5.68M, which affected share count and dilution to existing holders.
• This filing does not disclose replacement financing or other capital-raising plans — investors may want to monitor further announcements for alternative funding sources or impact on liquidity.